Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein kinase D (PKD) isoforms are involved in controlling tumor cell motility, angiogenesis, and metastasis.
|
24336522 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein Kinase D1 (PrKD1) functions as a tumor and metastasis suppressor in several human cancers by influencing cell-cycle progression.
|
30958903 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings demonstrate that recurrent and high-grade PACs are underpinned by PRKD1 E710D hotspot mutations or PRKD2 rearrangements, and that recurrences of PACs may stem from the selection of pre-existing subclones in the primary tumour.
|
30843621 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, the high levels of expression of PKD1, observed in highly proliferative cancers and tumors with poor prognosis, contribute to enhanced resistance to chemotherapy.
|
31167779 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our results suggest that PKD1 functions as a tumor and metastasis suppressor, at least partly by regulating Snail-mediated EMT, and that loss of PKD1 may contribute to acquisition of an aggressive malignant phenotype.
|
20940406 |
2010 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We identified PRKD1 hotspot mutations encoding p.Glu710Asp in 72.9% of PLGAs but not in other salivary gland tumors.
|
25240283 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These studies suggest that the LPA/PKD-1-CD36 signaling axis links DIO to malignant progression of BC via stimulation of de novo tumor arteriogenesis through arteriolar remodeling of microvasculature in the tumor microenvironment.
|
28186980 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Using an animal model, we show that reversion of PRKD1 promoter methylation with the DNA methyltransferase inhibitor decitabine restores PKD1 expression and blocks tumor spread and metastasis to the lung in a PKD1-dependent fashion.
|
23971832 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Studies in a xenograft mouse model indicate that PKD1 overexpression delayed tumor appearance, enhanced necrosis and lowered tumor hypoxia.
|
25149539 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, we have provided a comprehensive review of the reported tumor promoting or tumor suppressive functions of PKD in several major cancer types and discussed the discrepancies that have been raised on PKD as a major regulator of malignant transformation.
|
28577984 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study suggests that PKD1 may be a potential target for microenvironment-directed tumor biotherapy.
|
29901206 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, PKD-specific inhibitor significantly reduced tumor volume and tumor growth in mice bearing RM-1 prostate cancer cells, which was attributed to attenuation of mast cell recruitment and tumor angiogenesis.
|
30841931 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Early evidence suggested that the epithelia lining the cysts share neoplastic features, leading to the definition of PKD as a "neoplasm in disguise".
|
31816397 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of PKD isoforms is deregulated in various tumours and PKDs, in particular PKD2, have been implicated in the regulation of tumour angiogenesis.
|
23503467 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results demonstrated that (1) PACs/CASGs are underpinned by genetic alterations affecting PRKD genes; (2) despite the associations between PAC and PRKD1 hotspot mutations and CASG and PRKD1/2/3 fusion, such distinction is not absolute; and (3) there is of a novel genotypic-phenotypic association whereby fusion-positive tumors are usually located in the base of the tongue, show papillary architecture and have a high risk of nodal metastasis.
|
31492931 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, tumor angiogenesis was completely abolished in PKD1 morphants using the zebrafish/tumor xenograft angiogenesis assay.
|
23874489 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ROC analysis indicated 3.28 as a cut-off point, and thus 72 and 106 tumors with low and high PRKD1 mRNA expression were categorized.
|
23621299 |
2014 |